Latest Content

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

C4 Therapeutics and Roche expanded their partnership to develop next-generation degrader-antibody conjugates, a novel oncology approach designed to improve the precision and therapeutic index of traditional antibody-drug conjugates.

The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.

This disconnect between clinical efficacy and real-world utilization remains one of the most persistent challenges in lipid management.

Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.

In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual meeting, a Louisiana federal judge declines to block mail-order access to mifepristone while leaving open the possibility of a future ruling against it, and a Q&A examines how the pharmaceutical industry is navigating the compounding pressures of the Iran war and tariff uncertainty on global supply chains.

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process.

A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.

Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.

Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.

Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.